Hiroyuki Yoda

610 total citations
20 papers, 285 citations indexed

About

Hiroyuki Yoda is a scholar working on Molecular Biology, Oncology and Neurology. According to data from OpenAlex, Hiroyuki Yoda has authored 20 papers receiving a total of 285 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 13 papers in Oncology and 6 papers in Neurology. Recurrent topics in Hiroyuki Yoda's work include Cancer-related Molecular Pathways (7 papers), Neuroblastoma Research and Treatments (6 papers) and Cancer therapeutics and mechanisms (5 papers). Hiroyuki Yoda is often cited by papers focused on Cancer-related Molecular Pathways (7 papers), Neuroblastoma Research and Treatments (6 papers) and Cancer therapeutics and mechanisms (5 papers). Hiroyuki Yoda collaborates with scholars based in Japan, China and United States. Hiroyuki Yoda's co-authors include Hiroki Nagase, Toshinori Ozaki, Hirokazu Sugimoto, Kyoko Fujiwara, Takayoshi Watanabe, Atsushi Takatori, Nobuko Koshikawa, Takahiro Inoue, Osamu Shimozato and Ken‐ichi Shinohara and has published in prestigious journals such as Nature Communications, PLoS ONE and Cancer Research.

In The Last Decade

Hiroyuki Yoda

19 papers receiving 283 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Hiroyuki Yoda Japan 10 194 104 51 31 18 20 285
Viacheslav V. Senichkin Sweden 8 241 1.2× 93 0.9× 48 0.9× 11 0.4× 21 1.2× 13 302
Hilary D. Hinshaw United States 4 230 1.2× 120 1.2× 54 1.1× 12 0.4× 7 0.4× 4 325
Janet Early United States 9 326 1.7× 224 2.2× 45 0.9× 20 0.6× 10 0.6× 13 397
Federico Lucantoni Spain 10 183 0.9× 75 0.7× 84 1.6× 8 0.3× 27 1.5× 14 333
Aurora Chinnici Italy 6 207 1.1× 147 1.4× 70 1.4× 7 0.2× 26 1.4× 9 330
Tristan M. G. Kenney Canada 4 244 1.3× 49 0.5× 44 0.9× 6 0.2× 18 1.0× 6 297
Annick Causse France 8 241 1.2× 151 1.5× 57 1.1× 9 0.3× 11 0.6× 11 346
Li-Ya Chiu Germany 8 218 1.1× 84 0.8× 48 0.9× 5 0.2× 15 0.8× 9 267

Countries citing papers authored by Hiroyuki Yoda

Since Specialization
Citations

This map shows the geographic impact of Hiroyuki Yoda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroyuki Yoda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroyuki Yoda more than expected).

Fields of papers citing papers by Hiroyuki Yoda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hiroyuki Yoda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroyuki Yoda. The network helps show where Hiroyuki Yoda may publish in the future.

Co-authorship network of co-authors of Hiroyuki Yoda

This figure shows the co-authorship network connecting the top 25 collaborators of Hiroyuki Yoda. A scholar is included among the top collaborators of Hiroyuki Yoda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroyuki Yoda. Hiroyuki Yoda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
An, Zhenyi, Qi-Wen Fan, Linyu Wang, et al.. (2024). EGFR and EGFRvIII coopt host defense pathways promoting progression in glioblastoma. Neuro-Oncology. 27(2). 383–397. 4 indexed citations
3.
Yoda, Hiroyuki, et al.. (2024). Poly (ADP-ribose) polymerase inhibitor sensitized DNA damage caused by an alkylating pyrrole-imidazole polyamide targeting MYCN in neuroblastoma cells. Biochemical and Biophysical Research Communications. 735. 150794–150794. 2 indexed citations
4.
Lai, Xiaoyi, Takahiro Inoue, Hiroyuki Yoda, et al.. (2022). Use of DNA‐alkylating pyrrole‐imidazole polyamides for anti‐cancer drug sensitivity screening in pancreatic ductal adenocarcinoma. Cancer Medicine. 12(5). 5821–5832. 3 indexed citations
5.
Ôta, Yôko, Hiroyuki Yoda, Takahiro Inoue, et al.. (2021). Targeting anaplastic lymphoma kinase (ALK) gene alterations in neuroblastoma by using alkylating pyrrole-imidazole polyamides. PLoS ONE. 16(9). e0257718–e0257718. 2 indexed citations
6.
Mori, Yusuke, Hiroyuki Yoda, Hiroaki Soda, et al.. (2021). CD133 prevents colon cancer cell death induced by serum deprivation through activation of Akt‐mediated protein synthesis and inhibition of apoptosis. FEBS Open Bio. 11(5). 1382–1394. 8 indexed citations
7.
Yoda, Hiroyuki, Takahiro Inoue, Jason Lin, et al.. (2020). Targeting the mutant PIK3CA gene by DNA‐alkylating pyrrole‐imidazole polyamide in cervical cancer. Cancer Science. 112(3). 1141–1149. 13 indexed citations
8.
Yoda, Hiroyuki, et al.. (2019). Vitamin K3 derivative induces apoptotic cell death in neuroblastoma via downregulation of MYCN expression. Biochemistry and Biophysics Reports. 20. 100701–100701. 2 indexed citations
9.
Mori, Yusuke, Takehiro Ogata, Hiroyuki Yoda, et al.. (2019). PTPRK suppresses progression and chemo‐resistance of colon cancer cells via direct inhibition of pro‐oncogenic CD133. FEBS Open Bio. 9(5). 935–946. 12 indexed citations
10.
Lin, Jason, Hiroyuki Yoda, Takayoshi Watanabe, et al.. (2019). Estimating genome-wide off-target effects for pyrrole-imidazole polyamide binding by a pathway-based expression profiling approach. PLoS ONE. 14(4). e0215247–e0215247. 3 indexed citations
11.
Yoda, Hiroyuki, Takahiro Inoue, Jason Lin, et al.. (2018). Direct Targeting of MYCN Gene Amplification by Site-Specific DNA Alkylation in Neuroblastoma. Cancer Research. 79(4). 830–840. 31 indexed citations
12.
13.
Sugimoto, Hirokazu, Hiroyuki Yoda, Yuyan Zhu, et al.. (2016). Improvement of gemcitabine sensitivity of p53-mutated pancreatic cancer MiaPaCa-2 cells by RUNX2 depletion-mediated augmentation of TAp73-dependent cell death. Oncogenesis. 5(6). e233–e233. 18 indexed citations
14.
15.
Sugimoto, Hirokazu, Hiroyuki Yoda, Ken‐ichi Shinohara, et al.. (2015). Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death. Cell Death Discovery. 1(1). 15010–15010. 21 indexed citations
16.
Sugimoto, Hirokazu, Hiroyuki Yoda, Ken‐ichi Shinohara, et al.. (2015). Silencing of RUNX2 enhances gemcitabine sensitivity of p53-deficient human pancreatic cancer AsPC-1 cells through the stimulation of TAp63-mediated cell death. Cell Death and Disease. 6(10). e1914–e1914. 10 indexed citations
17.
Inoue, Takahiro, Takayoshi Watanabe, Nobuko Koshikawa, et al.. (2015). Inhibition of KRAS codon 12 mutants using a novel DNA-alkylating pyrrole–imidazole polyamide conjugate. Nature Communications. 6(1). 6706–6706. 80 indexed citations
18.
Ozaki, Toshinori, Hirokazu Sugimoto, Hiroyuki Yoda, et al.. (2014). Runt‐related transcription factor 2 attenuates the transcriptional activity as well as DNA damage‐mediated induction of pro‐apoptotic TAp73 to regulate chemosensitivity. FEBS Journal. 282(1). 114–128. 25 indexed citations
19.
Yoda, Hiroyuki, Keiichi Tabata, Motofumi Miura, et al.. (2012). Vitamin K3 Analogs Induce Selective Tumor Cytotoxicity in Neuroblastoma. Biological and Pharmaceutical Bulletin. 35(4). 617–623. 25 indexed citations
20.
Noda, Manabu, Hiroshi Shibai, Toyoki Watabe, et al.. (1998). Evaluation of charge-integrating amplifier with silicon MOSFETs for cryogenic readout. Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE. 3354. 247–247. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Viacheslav V. Senichkin Breakdown of academic impact, for papers by Hilary D. Hinshaw Breakdown of academic impact, for papers by Janet Early Breakdown of academic impact, for papers by Federico Lucantoni Breakdown of academic impact, for papers by Aurora Chinnici Breakdown of academic impact, for papers by Tristan M. G. Kenney Breakdown of academic impact, for papers by Annick Causse Breakdown of academic impact, for papers by Li-Ya Chiu
Rankless by CCL
2026